Skip to main content
Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

PredictLive143AccountSocial
MARKETSINVESTLIVE143

Medicine

Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
All markets
AI
Big Tech & Business
Education
Energy
Market Share
Medicine
Physics & Math
Public Health
Space
Tokens

Tech and science odds and guides

Release dates for AI models and gadgets

Will the FDA approve retatrutide?

Before Jan 1, 2028
1.73x
Before Jul 1, 2028
1.16x
$117,212 vol

Will the FDA approve CagriSema?

Before Jan 1, 2027
1.09x
Before Jul 1, 2027
1.08x
$11,487 vol

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
2.29x
No
1.57x
$10,885 vol

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before 2027
1.01x
before December
1.01x
$40,832 vol

When will Beam Therapeutics submit a BLA for Risto-cel?

before 2027
1.70x
before April 2027
1.13x
$30,660 vol

Will the FDA approve VERVE-102?

Before 2030
1.73x
Before 2031
1.42x
$1,819 vol

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before July 2027
1.10x
Before 2028
1.08x
$6,562 vol

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Mar 1, 2027
1.55x
Before Jan 1, 2027
4.73x
$27,110 vol

When will the FDA reclassify BPC-157 to Category 1?

Yes
15.6x
No
1.03x
$147,976 vol